CRENESSITY Trademark

Serial Number: 99021883

CRENESSITY is a trademark filed by Neurocrine Biosciences, Inc. on January 29, 2025. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Trademark Classes

Class 42 - Computer & Scientific

Scientific and technological services; industrial analysis and research services

Class 44 - Medical Services

Medical services; veterinary services; hygienic and beauty care for human beings or animals

Owner Contact Info

Neurocrine Biosciences, Inc. (241 trademarks)

6027 Edgewood Bend Court
San Diego, CA 92130

Entity Type: 03

Legal Representation

Attorney of Record

Allison Strickland Ricketts

3,333 trademarks filed View all →

Correspondence Address

Allison Strickland Ricketts Fross Zelnick Lehrman & Zissu, P.C.

151 West 42nd St., 17th Floor

New York, NY 10036

United States

Trademark Details

Filing Date

January 29, 2025

Registration Date

Not Registered

Published for Opposition

July 15, 2025

Goods & Services

Providing medical information; Providing medical information to patients, medical professionals in the field of other endocrine diseases and disorders; Providing medical information to insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders; on-line information services, namely, providing medical information to patients, medical professionals in the field of other endocrine diseases and disorders; on-line information services, namely, providing medical information to insurance companies in the field of congenital adrenal hyperplasia and other endocrine diseases and disorders

Providing medical research information; providing medical research information in the field of pharmaceuticals and clinical trials focusing on other endocrine diseases and disorders; Scientific research in the nature of conducting clinical trials for pharmaceutical preparations for the treatment of congenital adrenal hyperplasia and other endocrine diseases and disorders, for others; conducting post-authorization pharmaceutical research for the marketing of pharmaceutical preparations and evaluating epidemiological results